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Abstract
Background: Mycoplasma pneumoniae is responsible for acute respiratory tract infections (RTIs) common in
children and young adults. As M. pneumoniae is innately resistant to b-lactams antibiotics usually given as the first-
line treatment for RTIs, specific and early diagnosis is important in order to select the right treatment. Serology is
the most used diagnostic method for M. pneumoniae infections.
Results: In this study, we identified the M. pneumoniae ATP synthase beta subunit (AtpD) by serologic proteome
analysis and evaluated its usefulness in the development of a serological assay. We successfully expressed and
purified recombinant AtpD (rAtpD) protein, which was recognised by serum samples from M. pneumoniae-infected
patient in immunoblots. The performance of the recombinant protein rAtpD was studied using a panel of serum
samples from 103 infected patients and 86 healthy blood donors in an in-house IgM, IgA and IgG enzyme-linked
immunosorbent assay (ELISA). The results of this assay were then compared with those of an in-house ELISA with a
recombinant C-terminal fragment of the P1 adhesin (rP1-C) and of the commercial Ani Labsystems ELISA kit using
an adhesin P1-enriched whole-cell extract. Performances of the rAtpD and rP1-C antigen combination were further
assessed by binary logistic regression analysis. We showed that combination of rAtpD and rP1-C discriminated
maximally between the patients infected with M. pneumoniae (children and adults) and the healthy subjects for
the IgM class, performing better than the single recombinant antigens or the commercial whole-cell extract.
Conclusion: These results suggest that AtpD can be used as an antigen for the immunodiagnosis of early and
acute M. pneumoniae infection in association with adhesin P1, providing an excellent starting point for the
development of point-of-care diagnostic assays.
Background
Mycoplasma pneumoniae is a cell wall-less bacterium
belonging to the Mollicutes class, which invades the
human host respiratory epithelium by adhering with a
tip-like attachment organelle. Several proteins, including
the major surface adhesins P1, P30, P116 and proteins
HMW1 to HMW3, as well as proteins A, B and C,
interact to constitute this tip-like attachment organelle
[1-5]. M. pneumoniae causes atypical pneumonia and
other respiratory tract infections (RTIs) such as
tracheobronchitis, and is responsible for up to 20% of
all cases of community-acquired pneumonia, especially
among school-aged children and young adults [6,7].
M. pneumoniae is intrinsically resistant to beta-
lactams antibiotics usually given as the first-line
treatment of RTIs. Macrolides and related antibiotics
represent the treatment of choice for M. pneumoniae
respiratory infections. Therefore, an early and specific
diagnosis is necessary to give the patient the correct
antibiotic treatment.
Serology, including the complement fixation test
(CFT) and different enzyme-linked immunosorbent
assays (ELISA), is the most common laboratory method
used for the diagnosis of M. pneumoniae infection
although culture methods and PCR are also performed.
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antibodies to M. pneumoniae glycolipid antigens; thus, it
can react with antigens of different origins [7]. Previous
studies comparing the CFT to the PCR detection of
M. pneumoniae, however found good sensitivity and
specificity for the CFT [8,9]. Many ELISA-based assays,
using protein extracts, membrane preparations, glycoli-
pid extracts or whole cell lysates have been developed
for the detection of M. pneumoniae infection [8]. In par-
ticular, good sensitivity has been observed for assays
with P1 adhesin-enriched extracts [8,10,11]. In a study
by Beersma et al. [8], 12 commercial serologic assays for
M. pneumoniae specific immunoglobulins M and G and
the CFT were evaluated with PCR used as the “gold
standard”. The IgM assay that showed the best sensitiv-
ity and specificity were from the Ani Labsystems (77%
and 92%, respectively) corresponding to P1-enriched
extracts. Other studies have reported the superiority of
assays using the P1-enriched antigen on the basis of a
comparison of the strength of the immune response
[9,11,12]. Nonetheless in the same studies, high IgG ser-
oprevalence has been observed in the control sera ran-
ging from 36% (Virotech assay) to 93% (Ani Labsystems
assay). The variability of the ELISA results observed in
these studies suggests the need for improved sensitivity
and specificity among commercialised serological assays
used to detect M. pneumoniae infection [8].
Recently, many studies have reported great interest in
using a recombinant protein corresponding to the C-
terminal portion of the P1 adhesin, which has been
described as the immunodominant antigen in M. pneu-
moniae [2,13-17]. Antigenic properties of recombinant
proteins P116 and P30 have also been shown [15,18,19].
A combination of frequently recognized antigens could
be useful for diagnostic purposes. Thus, the identifica-
tion of antigenic M. pneumoniae RTI-related proteins
appears to be a prerequisite for the development of
serological test kits based on recombinant antigens.
In this study, we used serologic proteome analysis of
M. pneumoniae M129 total extracts to simultaneously
identify candidate antigens inducing an antibody
response [20]. We focused on the ATP synthase beta
s u b u n i t( A t p D )o fM. pneumoniae as it was likely to
generate an antibody response in M. pneumoniae-
infected children and adults at an early stage of infec-
tion. The atpD gene (mpn598) contains an open reading
frame of 1,428 nucleotides and encodes a protein of
475 amino acids, with a calculated molecular weight of
52,486 Da [21-23]. It was cloned and expressed in
E. coli to obtain recombinant protein. We then com-
pared the serological performance of this antigen with a
previously described recombinant C-terminal fragment
of the P1 adhesin (rP1-C) [2,13,15], using in-house
IgM, IgA and IgG ELISAs and the commercial Ani
Labsystems ELISA that uses an adhesin P1-enriched
whole extract. We further evaluated the performance of
the combination rAtpD and rP1-C IgM by binary logis-
tic regression analysis to compare results between the
recombinant antigens, either alone or together, and the
enriched whole extract.
Results
Identification of the AtpD antigen by serologic proteome
analysis
The total protein fraction obtained from the M. pneu-
moniae M129 strain was separated by two dimensional
gel electrophoresis (2D-E) (Fig. 1A) and the staining pat-
tern of the 2D immunoblots was probed with 10 differ-
ent serums samples from patients with RTIs (Fig. 1B) or
healthy blood donors (Fig. 1C). The protein identities of
six spots that were detected by at least one of the serum
samples from the 10 RTI patients were determined
using MALDI-TOF mass spectrometry following in-gel
tryptic digestion (Table 1). Of the six proteins identified,
four (P1 protein, enolase, the ATP synthase beta subunit
and the pyruvate dehydrogenase beta subunit) were
highly detected by serum samples from patients (Fig.
1B), but only two proteins, the P1 protein and the ATP
synthase beta subunit, showed no reactivity with serum
samples from healthy blood donors (Fig. 1C).
Expression, characterization and purification of rAtpD and
rP1-C proteins
The atpD gene and the C-terminal fragment of p1 were
amplified by PCR and expressed in E. coli BL21 (DE3)
cells after cloning into the expression vector pDEST 17.
These proteins were further purified by affinity column
and ion exchange chromatography. The expression and
purification of the rAtpD and rP1-C proteins were ana-
lysed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and western blot (Fig. 2). Two
irrelevant purified his-tagged recombinant proteins of
the same mass as rAtpD (Fig. 2, lane 6) and rP1-C (Fig.
2, lane 7) were included in the analysis. Both rAtpD and
rP1-C were successfully expressed in E. coli (Fig. 2A,
lane 2 for rAtpD and lane 3 for rP1 -C) and purified
with a purity estimated to be 100% by densitometry
(Fig. 2A, lane 4 for rAtpD and lane 5 for rP1-C). The
apparent molecular masseso fr A t p Da n dr P 1 - Cw e r e
about 40 and 50 kDa, respectively, in agreement with
the theoretical values.
The rAtpD and rP1-C proteins were both recognised
by pooled M. pneumoniae-positive serum samples (Fig.
2 B ,l a n e s2a n d4f o rr A t p D ,l a n e s3a n d5f o rr P 1 - C ) ,
but not by healthy blood donors (Fig. 2C, lanes 2 and 4
for rAtpD, lanes 3 and 5 for rP1-C). The two irrelevant
proteins were not recognised by serum samples from
either patients or healthy blood donors (Fig. 2B and 2C,
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infected patients have circulating anti-AtpD and anti-
rP1 -C antibodies, thereby confirming that these two
recombinant proteins are antigenic.
rAtpD and rP1-C ELISA tests
Serum samples from 103 patients (54 children, 49
adults) with M. pneumoniae RTIs and 86 healthy blood
donors were screened for anti-M. pneumoniae IgM, IgA
and IgG antibodies using an in-house ELISA with
rAtpD and rP1-C (Tables 2 and 3). We set positive cri-
teria as a value above the cut-off determined by receiver
operating characteristics curve (ROC) analysis. The cut-
o f fv a l u e so ft h eI g M ,I g Aa n dI g GE L I S At e s t sw e r e
determined as an absorbance value of 0.4, 0.2, and 0.4,
respectively, for rAtpD, and of 0.4, 0.5 and 0.4, respec-
tively for rP1-C. The rAtpD protein demonstrated a
higher discriminating score (0.842 ≤ area under curve
(AUC) ≤ 0.943) than rP1-C for all of the Ig classes
in children and adults (Tables 2 and 3). Among the
54 serum samples from children tested, 38 (70%)
showed a high IgM titre compared with rAtpD, whereas
30 (56%) were IgA-positive and 42 (78%) were IgG-posi-
tive. Serum samples from 38 (70%) children were posi-
tive for IgM against the rP1-C protein, whereas
27 (50%) and 37 (69%) were IgA- and IgG-positive,
respectively (Table 2). Out of the 49 serum samples
from adults infected with M. pneumoniae, 33 (67%) and
22 (45%) tested positive for IgM antibodies against the
rAtpD and rP1-C proteins, respectively. Of these sam-
ples, 32 (65%) and 27 (55%) reacted with the rAtpD and
rP1-C proteins, respectively, for the IgA class, whereas
30 (61%) and 22 (45%) were IgG-positive for the rAtpD
and rP1-C proteins, respective l y( T a b l e3 ) .S p e c i f i c i t y
values ranging from 90% to 97% were found for IgM,
IgA and IgG rAtpD and rP1-C protein ELISAs, meaning
that no more than 3% to 10% of the serum samples
from healthy donors had absorbance values above the
cut-off (Tables 2 and 3).
Serum samples from 39 (72%) children and 24 (49%)
adults were IgM-positive based on the Ani Labsystems
ELISA. The IgA and IgG Ani Labsystems EIA assays
showed the best sensitivity for serum samples from both
children and adult patients, with IgA being detected in
46 (85%) children and 48 (98%) adults and IgG being
detected in 52 (96%) children and 48 (98%) adults
(Tables 2 and 3). It should be noted that although the
IgM Ani Labsystems showed good specificity for chil-
dren and adults (92%), its specificity for IgA and IgG
were much lower, at 56% and 29%, respectively (Tables
2 and 3). Indeed, 44% (38/86) and 71% (61/86) of the
blood donor serum samples were found to be positive
by the IgA and IgG Ani Labsystems commercial kits,
respectively (Tables 2 and 3).
A
B
C
1
2
4
3
5
6
1
2
4
3
5
6
2
3
5
6
150
100
75
50
37
25
20
15
150
100
75
50
37
25
20
15
150
100
75
50
37
25
20
15
5                    pH                     8
Figure 1 2D-E profile of M. pneumoniae M129 total extract and
immunoblots. 2D-E profile of total extracts (A) and immunoblots
probed with 10 serum samples from RTI patients infected with M.
pneumoniae (B) or 10 serum samples from healthy blood donors (C).
Labelled spots represent the M. pneumoniae antigenic proteins that
were detected with serum samples from the study population. The
gel spots were encoded using a protein number (Table 1), which
was assigned based on their similar locations on different gels/
membranes.
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IgM, between two- and three-fold, was detected between
the first (acute-phase serum) and second of the six
paired serum samples. A two-fold increase in the IgA
and IgG responses was also seen between the first and
second samples (data not shown).
Statistical analysis of the rAtpD - rP1 combination
To evaluate whether a combination of multiple antigens
increased the ability to distinguish patients with RTIs
from healthy donors, we compared the seroreactivity
with a single antigen (rAtpD or rP1-C protein) to a com-
bination of these antigens and to a P1-enriched total
extract from the Ani Labsystems kit (Tables 2 and 3,
Fig. 3 and 4).
The AUC score increased with the number of recog-
nised antigens, going from 0.854 for a single recognised
antigen to 0.925 for two recognised antigens for IgM
class in children and from 0.708 to 0.923 for the IgM
class in adults. Moreover, the AUC scores of the combi-
nation of the IgM class were higher in children and
adults than the respective scores seen with the Ani
Labsystems kit (Tables 2 and 3, Fig. 3 and 4).
The rAtpD - rP1-C ELISA IgM combination showed
the best sensitivity, detecting 40 (74%) and 39 (80%) of
the serum samples from infected children and adults,
respectively, compared with the sensitivity obtained with
the recombinant antigens alone or the P1-enriched total
extract from the Ani Labsystems kit (Tables 2 and 3,
Fig. 3 and 4). Combination of the two antigens primarily
improved the IgM sensitivity for adult serum samples
(Table 3, Fig. 4).
The best sensitivity for the detection of IgG and IgA
in serum samples from children and adults sera was
Table 1 Antigenic proteins
a identified in this study
Spot no.
b Gene no.
c Protein name No. of matching peptides Sequence coverage (%) pI
d Mass (Da)
d
1 MPN141 Adhesin P1 24 16 6.4 176.2
2 MPN573 Heat shock protein GroEl 30 59 5.5 58.1
3 MPN606 Enolase 14 45 6.1 49.3
4 MPN598 ATP synthase beta subunit 29 80 5.4 52.3
5 MPN392 Pyruvate dehydrogenase E1 b subunit 21 57 6.2 40.6
6 MPN025 Fructose bisphosphate aldolase 10 44 6.4 31.3
a Antigenic proteins were separated by 2-DE, and their identities were determined by peptide mass fingerprinting.
b Spot numbers are shown in Fig. 1.
c Gene number in M. pneumoniae M129.
d Values for pI and mass are theoretical values from the deduced amino acid sequence of the identified gene and open reading frame, respectively.
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Figure 2 SDS-PAGE (A) and western blot analysis (B, C) of expressed and purified recombinant proteins. (A) SDS-PAGE analysis of the
expression of rAtpD and rP1-C in E. coli extracts (lanes 2 and 3 for rAtpD and rP1-C, respectively) and of the purified recombinant proteins (lanes
4 and 5 for rAtpD and rP1-C, respectively). Two irrelevant his-tagged proteins of the same mass as rAtpD (lane 6) and rP1-C (lane 7) were
purified and included in the study. (B, C) Western blot analysis of the expression of rAtpD and rP1-C in E. coli extracts (lanes 2 and 3,
respectively), of the purified recombinant proteins (lanes 4 and 5 for rAtpD and rP1-C, respectively) and of the two irrelevant his-tagged proteins
of the same mass as rAtpD (lane 6) and rP1-C (lane 7) with a pool of 10 serum samples from M. pneumoniae-positive patients (B) and with a
pool of 10 healthy blood donors (C). Lanes: 1, standard protein marker; 2, induced rAtpD (about 50 kDa); 3, induced rP1-C (about 40 kDa); 4,
purified rAtpD; 5, purified rP1-C; 6, irrelevant his-tagged protein of the same mass as rAtpD; 7, irrelevant his-tagged protein of the same mass as
r P1-C. The numbers on the left indicate molecular masses (in kDa).
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enriched total extract. Nonetheless, with regard to speci-
ficity, no more than 10% (9/86) of the blood donor
serum samples were detected positive for IgA and IgG
by the recombinant protein combination, contrasting
with the 44% (38/86) and 71% (61/86) found to be posi-
tive for IgA- and IgG, respectively, with the Ani Labsys-
tems kit (Tables 2 and 3).
Cross-reaction studies
We preliminarily evaluated the specificity of the rAtpD
ELISA-based assay for IgM, IgA and IgG with a panel of
55 serum samples from patients with non-M. pneumoniae
RTIs including Chlamydia pneumoniae (n = 18), Legio-
nella pneumophila (n = 10), Coxiella burnetii (n = 10),
Streptococcus pneumoniae (n = 8), Bordetella pertussis
(n = 8) and Chlamydia psittaci (n = 1). The rAtpD ELISA
assay showed good specificity (≥ 94.5%) for all three anti-
body classes, with no more than 3 of the 55 serum samples
cross-reacting (Table 4).
Discussion
Respiratory disease due to M. pneumoniae can be
assessed by serological methods, and of these the CFT
and ELISA are most widely used. The conserved C-
terminal region of the P1 adhesin (rP1-C) was recently
Table 2 Performance of the rAtpD, rP1-C ELISAs and the Ani Labsystems kit in children
Ig class Type of test No. of positive sera in Sensitivity
(95% CI)
Specificity
(95% CI)
AUC
Patients
a (54) Controls
b (86)
M rAtpD 38 3 70% (58%-83%) 97% (93%-100%) 0.923
M rP1-C 38 9 70% (58%-83%) 90% (83%-96%) 0.897
M rAtpD-rP1-C 40 5 74% (60%-80%) 94% (89%-99%) 0.925
M Ani Labsystems 39 7 72% (60%-84%) 92% (81%-97%) 0.824
A rAtpD 30 5 56% (42%-69%) 94% (89%-99%) 0.842
A rP1-C 27 7 50% (37%-63%) 92% (86%-98%) 0.775
A rAtpD-rP1-C 31 8 57% (44%-71%) 91% (89%-99%) 0.842
A Ani Labsystems 46 38 85% (77%-95%) 56% (45%-66%) 0.801
G rAtpD 42 3 78% (67%-89%) 97% (93%-100%) 0.943
G rP1-C 37 9 69% (56%-81%) 90% (83%-96%) 0.869
G rAtpD-rP1-C 43 5 80% (69%-90%) 94% (89%-99%) 0.925
G Ani Labsystems 52 61 96% (91%-100%) 29% (19%-39%) 0.663
aChildren infected by M. pneumoniae.
bHealthy blood donors.
Table 3 Performance of the rAtpD, rP1-C ELISAs and the Ani Labsystems kit in adults
Ig class Type of test No. of positive sera in Sensitivity
(95% CI)
Specificity
(95% CI)
AUC
Patients
a (49) Controls
b (86)
M rAtpD 33 8 67% (54%-80%) 91% (85%-97%) 0.877
M rP1-C 22 9 45% (31%-59%) 90% (83%-96%) 0.708
M rAtpD-rP1-C 39 7 80% (68%-91%) 92% (86%-98%) 0.891
M Ani Labsystems 24 7 49% (35%-61%) 92% (81%-97%) 0.685
A rAtpD 32 5 65% (52%-78%) 94% (89%-99%) 0.894
A rP1-C 27 9 55% (41%-69%) 90% (83%-96%) 0.779
A rAtpD-rP1-C 36 9 73% (61%-86%) 90% (83%-96%) 0.841
A Ani Labsystems 48 38 98% (94%-100%) 56% (45%-66%) 0.803
G rAtpD 30 3 61% (48%-75%) 97% (93%-100%) 0.877
G rP1-C 22 9 45% (31%-59%) 90% (83%-96%) 0.708
G rAtpD-rP1-C 33 1 67% (54%-80%) 99% (97%-100%) 0.891
G Ani Labsystems 48 61 98% (94%-100%) 29% (19%-39%) 0.734
aAdults infected by M. pneumoniae.
bHealthy blood donors.
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Page 5 of 13confirmed as the main antigen for the immunodiagnosis
of M. pneumoniae infections [13,16].
This work reports the first immunoproteomic study
for M. pneumoniae, leading to the identification of new
antigenic proteins such as the ATP synthase beta subu-
nit, enolase, the pyruvate dehydrogenase beta subunit
(PDH-B) and fructose bisphosphate aldolase. Antibodies
against the GroEl protein have previously been reported
in serum samples from patients with RTIs [24]. All of
the antigens described in this study, except the enolase
protein, were previously described as “proteins of the
Triton X-100 insoluble fraction of M. pneumoniae“ [25].
These proteins may be associated or bound to a cytos-
keleton-like structure, which could provide the neces-
sary framework to maintain and stabilize the shape of
M. pneumoniae [26], to allow motility [27] and to allow
the formation of an asymmetric cell. The correct assem-
bly of this organelle is a prerequisite for the binding of
M. pneumoniae to specific receptors on the host cell
[28,29]. Previous studies have demonstrated that the
enolase and the PDH-B protein in addition to their
major biosynthetic and metabolic roles in the cytoplasm,
could be translocated to the surface to serve as plasmi-
nogen- and fibronectin-binding proteins, respectively,
facilitating interactions between mycoplamas and the
extracellular matrix [30,31]. Thus, these data suggest a
pivotal role for these proteins in the infection mechan-
ism of M. pneumoniae.
Serologic proteome analysis showed that the AtpD
and the P1 proteins were highly detected by serum sam-
ples from patients with RTIs and not from healthy
blood donors. The other proteins identified were less
able to discriminate between patients and controls as
they were lightly antigenic to blood donors (confirmed
with further ELISA studies, data not shown). Thus the
AtpD and the rP1-C proteins were selected for further
serological study focusing on comparisons of the perfor-
mance of assays using these recombinant proteins with
assays using adhesin P1-enriched total extracts such as
the commercial Ani Labsystems kit.
To this end, the atpD gene and the P1-C sequence
were cloned, expressed in E. coli,a n dp u r i f i e d .T h e
1-specificity
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Figure 3 ROC analysis of the IgM rAtpD, rP1-C ELISAs, alone or combined, and the Ani Labsystems kit in children. ROC curves for each
assay. Black line represent rAtpD (AUC = 0.923), dark gray line rP1-C (AUC = 0.897), black dotted line rAtpD-rP1-C combination (AUC = 0.925),
light gray line Ani Labsystems (AUC = 0.824), gray dotted line median (AUC = 0.5).
Nuyttens et al. BMC Microbiology 2010, 10:216
http://www.biomedcentral.com/1471-2180/10/216
Page 6 of 13serological performance of the two recombinant pro-
teins either alone or in combination (logistic regression
analysis), and of the Ani Labsystems kit were further
compared using a panel of 103 serum samples from
M. pneumoniae-infected patients (54 children and
49 adults) and 86 serum samples from healthy blood
donors. The rAtpD protein-based assay, either alone or
in combination with rP1-C, identified more patient
serum samples (children or adults) than the Ani Labsys-
tems test for IgM, but fewer than the Ani Labsystems
EIA tests for IgA and IgG. In particular, 80% of the
serum samples from infected adult were found to be
IgM-positive by the combination of the two antigens
compared with 70%, 44% and 48% by rAtpD alone, rP1-
C alone and the Ani Labsystems assay, respectively
(Table 3). Previous studies have shown that young peo-
ple tend to have higher level of IgM antibodies in acute
infections, while adults may lack IgM during this phase
[7]. In recent studies, however, most of the IgM assays
tested showed inaccurate sensitivity ranging from 30 to
1-specificity
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Figure 4 ROC analysis of the IgM rAtpD, rP1-C ELISAs, alone or combined, and the Ani Labsystems kit in adults. ROC curves for each
assay. Black line represent rAtpD (AUC = 0.877), dark gray line rP1-C (AUC = 0.708), black dotted line rAtpD-rP1-C combination (AUC = 0.891),
light gray line Ani Labsystems (AUC = 0.685), gray dotted line median (AUC = 0.5).
Table 4 Cross-reactivity study with the IgM, IgA and IgG rAtpD recombinant protein-based ELISA tests
No. of sera with false-positive results by the rAtpD ELISA assay for
Sera from patients infected with (no. of sera tested) IgM IgA IgG
C. pneumoniae (18) 3 0 0
L. pneumophila (10) 0 0 0
C. burnetii (10) 0 1 0
S. pneumoniae (8) 0 2 0
B. pertussis (8) 0 0 0
C. psittaci (1) 0 0 0
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Page 7 of 1380% [8,32]. Thus the good sensitivity of the rAtpD -
rP1-C combination, especially in adults, seems promis-
ing and could be suitable for a rapid IgM assay [33].
When studying responses of healthy blood donors, the
rAtpD or rP1-C or rAtpD-rP1-C based assay detected a
few sera positive for IgM, IgA and IgG. In contrast, a
high number was detected positive with the IgA and
IgG-EIA Ani Labsystems assays. Such a high IgG sero-
prevalence in the control serum samples has been
observed in previous studies with the same kit [8,12],
suggesting the possibility of false-positive results for that
assay. The evaluation of the performance of IgG assays,
however, is complicated by the lack of information on
previous M. pneumoniae infections for the control
serum samples. As described in a previous study of the
prevalence of M. pneumoniae IgG and IgA antibodies in
a healthy population [34], the seroprevalence increases
with age but doesn’t exceed 58% for IgG or 28% for
IgA, even among the ederly. The elevated levels of spe-
cific M. pneumoniae IgG antibodies may be caused by
past M. pneumoniae infections [32,35]. In addition, a
variety of non specific antibodies may develop in asso-
ciation with M. pneumoniae infection due to the
sequence homology of adhesin proteins and glycolipids
of the M. pneumoniae cell membrane with mammalian
tissues [7,12].
The IgA and IgG assays using recombinant proteins
(alone or in combination) may lack sensitivity compared
to the results obtained with the commercial assay.
Nonetheless, the use of recombinant proteins may be
more specific than the whole extract used in the Ani
Labsystems assays, avoiding the detection of cross-reac-
tive antibodies to M. pneumoniae. Many studies have
reported the advantage of using a purified recombinant
protein in serodiagnosis arguing that better defined anti-
gen preparations should give more accurate results and
should be more specific than the use of a glycolipid or
whole-cell antigen [17,36,37].
Preliminary cross-reactivity studies were performed to
assess the specificity of the rAtpD ELISA assay and
showed weak cross-reactivity with other organisms
involved in respiratory disease, including S. pneumoniae,
C. pneumoniae and C. psittaci, L. pneumophila, B. per-
tussis and C. burnetii. Three serum samples from C.
pneumoniae-infected patients and two serums samples
from S. pneumoniae-infected patients were detected by
the rAtpD assay. This could have been due to antigeni-
cally similar epitopes, but we could not exclude the pos-
sibility of co-infection as these serum samples were
f o u n dt ob ep o s i t i v eb yt h er P 1 - Ca s s a y ,a sw e l l( d a t a
not shown). These data suggest a low risk of cross-reac-
tivity of this assay with an immune response to other
respiratory tract bacterial infections, but more RTI
serum samples should be tested to confirm these results.
The false-positive results could be also explained by
cross-reactivity between the rAtpD proteins of M. pneu-
moniae and M. genitalium, a phylogenetically closely
related species to M. pneumoniae. However, we were
not able to collect and study some serum samples from
M. genitalium-infected patients as the diagnosis of these
infections is only based on molecular methods. It would
be very interesting to further include some serum sam-
ples from M. genitalium-infected patient in the study.
Conclusion
In summary, this study presents a new antigen, AtpD,
that could contribute to improvements in the diagnosis
of M. pneumoniae infection in the early and acute phase
and could be more specific than the commercial assays
using complex extracts. We have shown that the combi-
nation of rAtpD with rP1-C antigen to detect IgM con-
tributed to improvements in the early specific diagnosis
of M. pneumoniae infection. Indeed, several studies have
recently reported that combination of selected antigens
provide higher sensitivity than single antigens [38].
Methods
Organisms and growth conditions
The M. pneumoniae reference strain M129 (ATCC
29342) was cultured in SP4 medium containing phenol
red used as pH indicator. Tissue culture flasks (Nunc)
were incubated at 37°C and inspected daily for colour
changes. The exponential growth phase was indicated by
a colour change in medium from red to orange-yellow.
The cells were harvested at this stage and washed in
phosphate buffered saline (PBS) and the pellet was
stored at -20°C.
Patients and healthy blood donors
From January 2004 to December 2006, serum samples
were retrospectively selected from 103 patients (54 chil-
dren, 1-15 years of age and 49 adults, 17-82 years of
age), admitted to Pellegrin hospital (Bordeaux, France),
Cochin hospital (Paris, France), and Raymond Poincaré
hospital (Garches, France) with a diagnosis of M. pneu-
moniae RTI. All of the serum samples were found to be
positive for M. pneumoniae by serodiagnosis, along with
a positive direct diagnosis for some patients, with either
culture or PCR. Depending on the laboratory where the
M. pneumoniae serodiagnosis was done, the serological
methods used were either the CFT (Virion Antigen) and
a commercial IgM ELISA test (Platelia EIA, Bio-Rad,
ImmunoCard Mycoplasma Test, Meridian) or a combi-
nation of IgM and IgG ELISAs (ImmunoWell IgM, IgG
EIA, BMD). Six paired serum samples were collected
with an acute-phase sample and a convalescent sample
obtained at least two weeks after the first sample. A
control group consisting of 86 single serum samples
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was obtained from the French establishment of blood
(Rungis, France) and diagnosed as M. pneumoniae-nega-
tive by the CFT and an IgM ELISA test (Platelia, Bio-Rad).
Furthermore, the specificity of the rAtpD protein-based
ELISAs was assessed using 55 additional serum samples,
18 that were positive for a C. pneumoniae infection
(National Reference Center for Chlamydiae,U n i v e r s i t é
Victor Segalen Bordeaux 2, France), 10 that were positive
for a L. pneumophila infection (National Reference Cen-
ter for Legionella, Université Lyon 1, France), 10 that
were positive for a C. burnetii infection (Pellegrin hospi-
tal, Bordeaux, France), 8 that were from patients harbor-
ing a S. pneumoniae RTI (Raymond Poincaré hospital,
Garches, France), 8 that were positive for a B. pertussis
infection (Marcel Merieux Laboratory, Lyon, France), and
1 that was positive for a C. psittaci infection (National
Reference Center for Chlamydiae,U n i v e r s i t éV i c t o r
Segalen Bordeaux 2, France). The present project is in
compliance with the Helsinki Declaration (Ethical Princi-
ples for Medical Research Involving Human Subjects).
The study was done in accordance with the guidelines of
the ethical committees of the participating hospitals. In
each hospital, specimens were collected as part of the
routine management of patients without any additional
sampling, and patients provided no objection for their
samples to be used. According to the French legacy, this
study did not need to be examined by the French
“Comité pour la Protection des Personnes” and allowed
the exemption of patient’s written informed consent. All
patient data shown in the present work were anon-
ymously reported, without offering any possibility to
trace the actual patients.
2D-E
The bacterial pellet were suspended in rehydratation
solution (Ready-Prep 2-D Rehydratation/Sample Buffer
1, Bio-Rad) composed of 7 M urea, 2 M thiourea, 1%
(wt/vol) ASB-14 detergent, 40 mM Tris, 4% 3[(3-chola-
midopropyl)-dimethylammonio]-1-propanesulfate
(CHAPS), 0.2% (vol/vol) immobilised pH gradient (IPG)
buffer, pH 3-10, 20 mM dithiothreitol (DTT) and
0.002% bromophenol blue. Cell lysis was performed by
sonication three times 20 s (Branson Sonifier), and the
un-disrupted cells were removed by centrifugation
(20,817 × g; 45 min; 21°C). Total protein concentration
was determined using a 2-D Quant kit (GE Healthcare)
according to the manufacturer’si n s t r u c t i o n s .T h ep r o -
tein concentration was calculated using bovine serum
albumin (BSA) as a standard.
Isoelectric focusing was performed using the Protean
IEF Cell system and Immobilised pH gradient (IPG)
strips with a pH range of 5-8 (Bio-Rad). Two hundred
and fifty μg of the protein samples in 150 μlo f
rehydratation solution was used to rehydrate the IPG
strips (7 cm, pH 5-8) overnight at 20°C under mineral
oil. The proteins were focused for 10 kVh with a maxi-
mum voltage of 4,000 V at 20°C. After focusing, the
strips were incubated for 10 min in 2 mL of equilibra-
tion buffer I (6 M urea, 2% SDS, 375 mM Tris-HCl, pH
8.8, 20% glycerol, 130 mM DTT), followed by equilibra-
tion buffer II (6 M urea, 2% SDS, 375 mM Tris-HCl, pH
8.8, 20% glycerol, 135 mM iodoacetamide). The equili-
brated IPG strips were then drained and embedded on
top of 12.5% acrylamide gels, and electrophoresis was
c a r r i e do u ta t2 5Vf o r2 0m i n ,a n da t1 8 0Vf o r6h .
Protein molecular weight markers (Bio-Rad) were used.
Proteins were visualised by staining with Coomassie
blue. Gel images were captured by a GS-800 densit-
ometer (Bio-Rad). Replicate gels were generated from
two independent experiments, and one representative
gel is shown. The control immunoblot was incubated
with the secondary antibody without any human serum
and failed to yield any signal.
Western blot
For western blot analysis, the proteins separated by elec-
trophoresis were transferred to nitrocellulose mem-
branes (0.45 μm, Bio-Rad) [39] and blocked in Tris-
buffered saline (TBS) containing 3% non-fat dry milk.
The membranes were probed with anti-M. pneumoniae
antibody-positive pooled human serum or healthy blood
donor pooled serum (n = 10) at a dilution of 1:500 in
blocking buffer. The blots were washed with TBS con-
taining 0.05% Tween 20 (TBST). Goat anti-human alka-
line phosphatase conjugate (Sigma-Aldrich) was used as
secondary antibody (1:2,000 dilution). Blots were then
incubated with p-nitroblue tetrazolium chloride and
5-bromo-4-chloro-3-indolyl phosphate p-toluidium salt
(BCIP) solution (Sigma-Aldrich) until colour develop-
ment had reached the desired level (2 to 3 min).
Protein identification and mass spectrometry
Selected protein spots were excised from the 2D-E gels
using a sterile scalpel and placed into 96 well plates.
The gel pieces were further subjected to in-gel tryptic
digestion as previously described [40] with minor modi-
fications. The gel pieces were washed three times in
MilliQ water, dehydrated in acetonitrile, and dried in a
vacuum centrifuge. They were then rehydrated at 4°C
for 15 min in digestion buffer containing 50 mM
NH4HCO3 and 12.5 ng/μl trypsin (modified sequencing
grade, Promega). The supernatant was replaced with
30 μlo f5 0m MN H 4HCO3, and the samples were incu-
bated overnight at 37°C. Digested peptides contained in
the supernatant were purified using a home-made
micropurification column containing 0.1 μlo f2 0 R 2
reversed-phased material (PerSeptive Biosystems) packed
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1% trifluoroacetic acid. Ten μl of the supernatant was
then loaded onto the column. After washing with 1%
trifluoroacetic acid, the adsorbed peptides were eluted
directly onto a MALDI target (MTP AnchorChip 600/
384, Bruker Daltonik) with 0.8 μl of 70% acetonitrile
and 0.1% trifluoroacetic acid containing saturated alpha-
cyano-4-hydroxycinnamic acid (Bruker Daltonik). Mass
fingerprints were acquired with a MALDI-TOF/TOF
mass spectrometer (Ultraflex; Bruker Daltonik) and pro-
cessed with FlexAnalysis 2.2 software and ProteinScape
1.3 (Bruker Daltonik). After internal calibration with
trypsin autodigestion peptides, the monoisotopic masses
of the tryptic peptides were used to query NCBInr
sequence databases (215, 9330197 sequences) using the
Mascot search algorithm (Mascot server version 2.2;
http://www.matrixscience.com). The search conditions
used were as followed: maximum mass error of 70 ppm,
one missed cleavage allowed, modification of cysteines
by iodoacetamide, and methionine oxidation as variable
modification. Identifications were based on the MAS-
COT score, observed pI and mass (kDa), number of
matching peptide masses and total percentage of the
amino acid sequence covered by the peptides. Sequence
coverage ranged from 16% to 80%.
PCR amplification, cloning and expression of the atpD
gene and the C-terminal fragment of the p1 gene (rP1-C)
of M. pneumoniae M129
Sequence cloning was done using the Gateway® technol-
ogy. This technology allows the efficient transfer of DNA
fragments into plasmids while maintaining the reading
frame, using a set of recombination sequences, “Gateway
att” sites, and two enzymes termed LR Clonase and BP
Clonase. Recombination sequences must be introduced
to the DNA fragments before cloning into Gateway® vec-
tors. Genomic DNA was extracted from M. pneumoniae
M129 with the DNA easy tissue kit (Qiagen) and used as
at e m p l a t ef o rP C Ra m p l i f i c a t i o no ft h eatpD gene
(mpn598, nucleotide positions 5′-719548-720975-3′ on
the complementary strand) and the C-terminal fragment
of the p1 gene (mpn141) encompassing amino acid resi-
dues 1159-1519 (nucleotide positions 5′-184335-185418-
3′). No codon changes were required for expression of
the sequences in E. coli. The following forward and
reverse primers were used for the amplification of
the atpD gene: 5′-AAAAAAGCAGGCTTGAAAAAG-
GAAAACATTACATACG-3′ (Fa) and reverse 5′-
AGAAAGCTGGGTTTTCTCCTCAACAGTAG-3′ (Ra).
The following forward and reverse primers were used
for the amplification of the p1 gene: 5′-AAAAAAG-
CAGGCTTGCGGCCTTTCGTGGCAGTTG-3′ (Fp)
and reverse 5′-AGAAAGCTGGGTGGTCACTGGT-
TAAACCGGAC-3′ (Rp). The 13 and 12 first nucleotides
of forward and reverse primers, respectively, represented
the first recombination sequence necessary for Gateway®
cloning. Other nucleotides of the Fa, Ra and Fp, Rp pri-
mers represent atpD and p1 sequences, respectively. PCR
was performed in a 25-μl reaction containing 0.075 U/μl
of Triple Master polymerase (Eppendorf), 2.5 μlo fH i g h
Fidelity Buffer with Mg
2+, 200 μM dNTPs, 200 nM of
each primer and 70 ng of extracted DNA. The reaction
conditions were standardised at an initial denaturation of
94°C for 5 min followed by 25 cycles of 94°C for 50 s,
54°C for 50 s, and 72°C for 1 min 20 s. A final extension
was done at 72°C for 5 min. PCR products were analysed
in a 1% agarose gel and purified using a QIA-quick PCR
purification kit (Qiagen). A second PCR using the same
conditions was performed to introduce the second
recombination sequence necessary for Gateway® cloning
by using 5′-GGGGACAAGTTTGTACAAAAAAG-
CAGGCT-3′ (Fg)a st h ef o r w a r dp r i m e ra n d5 ′-
GGGGACCACTTTGTACAAGAAAGCTGGGT-3 (Rg)
as the reverse primer. After purification, the PCR pro-
ducts were inserted into the Gateway® expression vector
pDEST17, as previously described [41]. The inserts were
then sequenced to rule out any mutations.
The ligation mixtures were transformed into E. coli
DH5a competent cells. Transformants were selected on
LB plates containing 100 μg/ml ampicillin, and the posi-
tive clones were confirmed by colony PCR with the Fg
and Rg primers. Plasmid DNA was isolated from positive
clones from overnight cultures using a Midi plasmid
purification kit (Qiagen). Fifty ng of plasmid DNA was
transformed into E. coli BL21 (DE3), and cells contain-
ing the recombinant plasmids were grown in 17 ml of
LB broth (containing 100 μg/ml ampicillin and 20 μg/ml
chloramphenicol) to an optical density at 600 nm
(OD600) of 0.3. Protein expression was induced by
0.5 mM IPTG (isopropyl-D-thiogalactopyranoside,
Sigma-Aldrich). Once the OD600 had reached 1, the bac-
teria were pelleted by centrifugation and further sub-
jected to SDS-PAGE as described by Laemmli [42] and
western blot to evaluate the expression and antigenicity
of the expressed recombinant proteins. The two proteins
were found to be expressed in inclusion bodies. The
expression protocol was specifically designed to increase
the quantity of expressed recombinant proteins in order
to facilitate further purification. Bacterial growth was
monitored by measuring absorbance at 600 nm. No
toxic effect due to the over-expressed recombinant
proteins was observed on E. coli cells.
Purification of recombinant rAtpD and rP1-C proteins
For large-scale production of recombinant proteins, 2l of
culture of E. coli cells expressing rAtpD and rP1-C were
grown and induced with 0.5 mM IPTG. After induction,
the bacterial pellet was obtained by centrifugation at
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lysis buffer (20 mM Tris HCl, pH8, 0.5 M sucrose,
100 mM EDTA, pH8, 2 mg/ml lysozyme, 1 mM phenyl-
methylsulfonyl fluoride (PMSF)). After incubation on ice
for 45 min, the tubes were centrifuged at 15,557 × g at
4°C for 10 min. The pellets were frozen at -20°C until
purification. The cells were then sonicated three times
with a 20 s pulse at 1-min intervals on ice in a sonica-
tion buffer (8 M urea, 20 mM triethanolamine, pH8,
500 mM NaCl, 25 mM imidazole, 1 mM PMSF). The
cells were harvested by centrifugation at 15,557 × g for
45 min with a buffer containing 20 mM triethanolamine,
pH8, 500 mM NaCl and 0.25 M imidazole and then
subsequently using buffers with the same composition
containing 1 M and 8 M urea. These three “wash steps”
were used to eliminate the majority of E. coli contami-
nants before purification. The supernatant of the final
step containing the protein of interest was filtered and
loaded onto a HisTrap column (GE Healthcare) at 4°C.
The proteins were eluted from the column by applying
ag r a d i e n to f0 . 2 5t o0 . 5Mi m i d a z o l ei nab u f f e rc o n -
taining 8 M urea, 20 mM triethanolamine, pH8,
500 mM NaCl. Fractions containing the recombinant
protein in large quantities without contaminants were
pooled and dialyzed against an ion exchange buffer
(6 M urea, 20 mM triethanolamine, pH8) overnight
using a nitrocellulose dialysis membrane (Spectra/Por®-
membrane kit, http://www.spectrumlabs.com) before
loading onto a HiTrap ion exchange Q column (GE
Healthcare). The proteins were eluted by applying a gra-
dient of 0 to 1 M NaCl in ion exchange buffer. The
fractions containing the recombinant proteins with a
high degree of purity were pooled and dialyzed against a
storage buffer (6 M urea, 20 mM triethanolamine, pH8,
300 mM NaCl, 5 mM EDTA). The protein concentra-
tion was determined by the Lowry method [43]. The
fractions were separated by 12.5% SDS-PAGE and the
purity of purified recombinant proteins was estimated
by densitometry (Quantity one software, GS 800 densit-
ometer, Bio-Rad). The purified proteins were instanta-
neously used for ELISA analysis, the proteins were then
conserved no longer than one month in storage buffer.
ELISAs with purified recombinant proteins rAtpD, rP1-C
and commercial Ani Labsystems kit
Serum samples collected from children and adult
patients with M. pneumoniae RTIs and from healthy
blood donors were screened for anti-M. pneumoniae
IgM, IgA and IgG antibodies by in-house ELISAs with
the rP1-C and rAtpD proteins. Preadsorption of IgG
rheumatoid factor was performed before each IgM
ELISA test. The purified proteins were diluted by suc-
cessive steps in PBS to avoid potentially damaging crys-
tallisation of the urea in our ELISA washer automates.
No precipitation of proteins was observed. Control
ELISA tests were performed at different urea concentra-
tions ranging from 8 M to 0.1 M. The reactivity of the
two recombinant proteins was not affected by stepwise
dilution as the variation of the ELISA values with con-
trol serum samples was insignificant. The 96-well Maxi-
sorp microtitre EIA plates (Nunc) were coated in
triplicate with 50 ng per well of rP1-C or rAtpD in PBS.
The plates were incubated overnight at 4°C and blocked
in 250 μl blocking buffer (4% bovine serum albumin in
PBS with 5 mM EDTA) at 37°C for 1 h. After washing
three times with PBS containing 0.05% Tween 20, the
antigen-coated wells were incubated sequentially for
30 min at 37°C with 1:100-diluted test sera, along with
1:50,000 dilution of peroxidase-labelled goat anti-human
IgM, or IgA, or a 1:200,000 dilution of peroxidase-
labelled goat anti-human IgG (Pierce). Plates were
washed three times with PBS containing 0.05% Tween
20 between incubations. The enzyme reaction was
developed with 100 μl of TMB (tetramethylbenzidine)
substrate (Medac) for 30 min at 37°C. The reaction was
stopped by adding 100 μlo f2MH 2SO4.T h ep l a t e s
were read by photometric reading at 450 nm using an
Opsys MR microplate reader (Dynex). “Blank” wells
containing no patient or control serum were included in
each assay. No high background was observed (OD450 ≤
0.05). Panels of serum samples from 103 patients and 86
healthy blood donors were screened for anti-M. pneu-
moniae IgM, IgG and IgA antibodies using the corre-
sponding Ani Labsystems EIA kits according to the
manufacturer’s instructions.
Statistical analysis
All results were analysed with the Tanagra software
1.4.31 (http://chirouble.univ-lyon2.fr/~ricco/tanagra/fr/
tanagra.html). The accuracy of the serological assays in
discriminating disease cases from normal cases was eval-
uated by using ROC curve plots [44]. ROC plots were
calculated by expressing the relationship between the
fraction “correctly identified to be positive” and the frac-
tion “falsely identified to be positive” for every possible
cut-off point selected to discriminate between the
patients and the blood donors. The AUC is a measure
of the assay efficiency to discriminate the “true posi-
tives” from the “true negatives”. The cut-off values for
every in-house serological assay were determined for
maximum efficiency of the test. A sample was consid-
ered positive if the antibody titre exceeded the defined
cut-off value. Binary logistic regression analysis was per-
formed before evaluating the performance of the antigen
combination by ROC plots as described above. Sensitiv-
ity, specificity and 95% confidence intervals (95% CI)
were calculated for rAtpD and rP1-C antigens, either
alone or in combination. The calculation of cut-off
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Labsystems kits were performed according to the manu-
facturer’s instructions.
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